comparemela.com

Latest Breaking News On - Jiang haiyang - Page 1 : comparemela.com

Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

/PRNewswire/ Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific.

United statesLiu huanHong kongGuiqiang wangAnn hepatolJiang haiyangGu shengwangHong kong stock exchangeUniversity first hospitalLiver disease centerInfectious diseases departmentAscletis pharma incAscletis pharmaAsian pacific associationPeking university first hospitalChinese hepatology

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

After the pre-Phase III clinical trial meeting with Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) in June 2022,.

United statesLiu huanHong kongJiang haiyangGu shengwangJinzij wuShanghai public health clinical centerChina national medical products administrationHong kong stock exchangeAscletis pharma incPrnewswire ascletis pharma incInternational liver congressDrug evaluationExpansion cohortEuropean associationPharma inc

vimarsana © 2020. All Rights Reserved.